Elevated Intact Proinsulin Levels are Indicative of Beta-Cell Dysfunction,Insulin Resistance,and Cardiovascular Risk: Impact of the Antidiabetic Agent Pioglitazone
Free accessResearch articleFirst published online May, 2011
Elevated Intact Proinsulin Levels are Indicative of Beta-Cell Dysfunction,Insulin Resistance,and Cardiovascular Risk: Impact of the Antidiabetic Agent Pioglitazone
Insulin resistance (IR) and deterioration of beta-cell secretion are main features in the development of type 2 diabetes, which is reflected in increasing serum intact proinsulin levels in later disease stage. Introduction of stable assays that are able to distinguish between intact proinsulin and its specific and unspecific cleavage products has resulted in the finding that serum intact proinsulin values can serve as a direct marker for beta-cell dysfunction, are a highly specific indicator of IR, and can predict cardiovascular risk.
Method:
Determination of fasting intact proinsulin may be used to monitor and optimize antidiabetic therapeutic approaches. Our study group has been involved in a variety of clinical studies investigating drug effects on beta-cell secretory capacity, IR, and intact proinsulin levels. One focus was on the impact of insulin-sensitizing therapy with pioglitazone on the pancreatic beta-cell load.
Results:
Treatment with pioglitazone resulted in significant decreases in elevated proinsulin levels in type 2 diabetes patients. This effect was independent from glycemic control.
Conclusions:
Measurement of fasting intact proinsulin values allows a staging of beta-cell dysfunction and evaluation of IR, thus providing an interesting diagnostic tool for both selection of appropriate therapy and monitoring of treatment success.
ReavenGMChenYDHollenbeckCBSheuWHOstregaDPolonskyKS. Plasma insulin, C-peptide, and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance. J Clin Endocrinol Metab.1993;76 (1): 44–8.
2.
HaffnerSMBowsherRRMykkänenLHazudaHPMitchellBDValdezRAGingerichRMonterossaASternMP. Proinsulin and specific insulin concentration in high- and low-risk populations for NIDDM. Diabetes.1994;43 (12): 1490–3.
3.
RøderMEPorteDJrSchwartzRSKahnSE. Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab.1998;83 (2): 604–8.
4.
HaffnerSMMykkänenLValdezRASternMPHollowayDLMonterrosaABowsherRR. Disproportionately increased proinsulin levels are associated with the insulin resistance syndrome. J Clin Endocrinol Metab.1994;79 (6): 1806–10.
5.
PfütznerAStandlEHohbergCKonradTStrotmannHJLübbenGLangenfieldMRSchulzeJForstT. IRIS II study: Intact proinsulin is confirmed as a highly specific indicator for insulin resistance in a large cross-sectional study design. Diabetes Technol Ther.2005;7 (3): 478–86.
6.
PfütznerAPfütznerAHLarbigMForstT. Role of intact proinsulin in diagnosis and treatment of type 2 diabetes mellitus. Diabetes Technol Ther.2004;6 (3): 405–12.
7.
PfütznerAPfütznerAHStriddeEHuppertzEReimerTDerwahlMForstTPetrakF. Insulin resistance and b-cell-dysfunction in insufficiently controlled type 2 diabetes: The SETT2D Trial. Diabetes Stoffwechsel Herz.2007;2: 91–7.
8.
PfütznerAWeberMMForstT. A biomarker concept for assessment of insulin resistance, beta-cell function and chronic systemic Inflammation in type 2 diabetes mellitus. Clin Lab.2008;54 (11–12): 485–90.
9.
PfütznerAKuntTHohbergCMondokAPahlerSKonradTLübbenGForstT. Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Diabetes Care.2004;27 (3): 682–7.
10.
PfütznerAKannPHPfütznerAHKuntTLarbigMWeberMMForstT. Intact and total proinsulin: New aspects for diagnosis and treatment of type 2 diabetes mellitus and insulin resistance. Clin Lab.2004;50 (9–10): 567–73.
11.
GallowayJAHooperSASpradlinCTHoweyDCFrankBHBowsherRRAndersonJH. Biosynthetic human proinsulin. Review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience. Diabetes Care.1992;15 (5): 666–92.
12.
PfütznerAKuntTLangenfeldMLöbigMKnesovicMForstT. Clinical and laboratory evaluation of specific chemiluminescence assays for intact and total proinsulin. Clin Chem Lab Med.2003;41 (9): 1234–8.
13.
PfütznerAPfütznerAHKannPHStuteRLöbigMYangJWMistryJForstT. Clinical and laboratory evaluation of a new specific ELISA for intact proinsulin. Clin Lab.2005;51 (5–6): 243–9.
14.
SiebenhaarRWeiseASafinowskiMReisingerKMusholtPBReimerTPfütznerAForstT. Clinical and laboratory evaluation of a new specific ELISA for intact proinsulin. Diabetes Stoffwechsel Herz.2008;2: 275–81.
15.
LindahlBDinesenBEliassonMRøderMJanssonJHHuhtasaariFHallmansG. High proinsulin concentration precedes acute myocardial infarction in a nondiabetic population. Metabolism.1999;48 (9): 1197–202.
16.
LindahlBDinesenBEliassonMRøderMHallmansGStegmayrB. High proinsulin levels precede first-ever stroke in a nondiabetic population. Stroke.2000;31 (12): 2936–41.
17.
NijpelsGPopp-SnijdersCKostensePJBouterLMHeineRJ. Fasting proinsulin and 2-h post-load glucose levels predict the conversion to NIDDM in subjects with impaired glucose tolerance: The Hoorn Study. Diabetologia.1996;39 (1): 113–8.
18.
ZetheliusBBybergLHalesCNLithellHBerneC. Proinsulin is an independent predictor of coronary heart disease: Report from a 27-year follow-up study. Circulation.2002;105 (18): 2153–8.
19.
AlssemaMDekkerJMNijpelsGStehouwerCDBouterLMHeineRJ; Hoorn Study. Proinsulin concentration is an independent predictor of all-cause and cardiovascular mortality: An 11-year follow-up of the Hoorn Study. Diabetes Care.2005;28 (4): 860–5.
20.
BåvenholmPProudlerATornvallPGodslandILandouCde FaireUHamstenA. Insulin, intact and split proinsulin, and coronary artery disease in young men. Circulation.1995;92 (6): 1422–9.
21.
WarehamNJByrneCDHalesCN. Role of insulin and proinsulin in diabetic vascular disease. Metabolism.1995;44 (10Suppl 4): 76–82.
22.
YudkinJSMayMElwoodPYarnellJWGreenwoodRSmithG Davey; Caerphilly Study. Concentrations of proinsulin like molecules predict coronary heart disease risk independently of insulin: Prospective data from the Caerphilly Study. Diabetologia.2002;45 (3): 327–36.
23.
KatzRJRatnerRECohenRMEisenhowerEVermeD. Are insulin and proinsulin independent risk markers for premature coronary artery disease?Diabetes.1996;45 (6): 736–41.
24.
JeppesenJHansenTWRasmussenSIbsenHTorp-PedersenCMadsbadS. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: A population-based study. J Am Coll Cardiol.2007;49 (21): 2112–9.
25.
LangenfieldMRForstTStandlEStrotmannHJLübbenGPahlerSKannPPfütznerA; IRIS II study. IRIS II Study: Sensitivity and specificity of intact proinsulin, adiponectin, and the proinsulin/adiponectin ratio as markers for insulin resistance. Diabetes Technol Ther.2004;6 (6): 836–43.
26.
KuboK. Effect of pioglitazone on blood proinsulin levels in patients with type 2 diabetes mellitus. Endocr J.2002;49 (3): 323–8.
27.
WallaceTMLevyJCMatthewsDR. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. Diabet Med.2004;21 (6): 568–76.
28.
PfütznerAHohbergCLübbenGPahlerSPfütznerAHKannPForstT. Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control. Horm Metab Res.2005;37 (8): 510–5.
29.
DorkhanMMagnussonMFridAGrubbAGroopLJovingeS. Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes. J Intern Med.2006;260 (2): 125–33.
30.
ForstTPfütznerALübbenGWeberMMarxNKaragiannisEKoehlerCBaurechtWHohbergCHanefeldM. Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk–the PIOSTAT Study. Metabolism.2007;56 (4): 491–6.
31.
ForstTWilhelmBPfütznerAFuchsWLehmannUSchaperFWeberMMüllerJKonradTHanefieldM. Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk. Diab Vasc Dis Res.2008;5 (4): 298–303.
32.
CooperMBAl MajaliKBaileyCJBetteridgeDJ. Reduced postprandial proinsulinaemia and 32–33 split proinsulinaemia After a mixed meal in type 2 diabetic patients following sensitization to insulin with pioglitazone. Clin Endocrinol (Oxf).2008;68 (5): 738–46.
33.
CharpentierGHalimiS; F-PIO-100 Study Investigators. Earlier triple therapy with pioglitazone in patients with type 2 diabetes. Diabetes Obes Metab.2009;11 (9): 844–54.
34.
HohbergCPfütznerAForstTLübbenGKaragiannisEBorchertMSchöndorfT. Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual beta-cell function: Results from the PioSwitch study. Diabetes Obes Metab.2009;11 (5): 464–71.
35.
MusholtPBSchöndorfTPfütznerAHohbergCKleineIFuchsWHehenwarterSDiktaGKerschgensBForstT. Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: Results from a pilot study. J Diabetes Sci Technol.2009;3 (6): 1442–50.
36.
PfütznerADerwahlMJacobSHohbergCBlümnerELehmannUFuchsWForstT. Limitations of the HOMA-B score for assessment of beta-cell functionality in interventional trials–results from the PIOglim study. Diabetes Technol Ther.2010;12 (8): 599–604.
37.
ForstTHohbergCFuellertSDLübbenGKonradTLöbigMWeberMMSacharaCGottschallVPfütznerA. Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes. Horm Metab Res.2005;37 (8): 521–7.
38.
SmithSAPorterLEBiswasNFreedMI. Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin: Insulin ratio in type 2 diabetes. J Clin Endocrinol Metab.2004;89 (12): 6048–53.
39.
OvalleFBellDS. Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes. Diabetes Care.2004;27 (11): 2585–9.
40.
PfütznerASchöndorfTSeidelDWinklerKMatthaeiSHamannAForstT. Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: Results from a double-blind oral combination study with glimepiride. Metabolism.2006;55 (1): 20–5.
41.
HanefieldMPatwardhanRJonesNP; Rosiglitazone Clinical Trials Study Group. A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes. Nutr Metab Cardiovasc Dis.2007;17 (1): 13–23.
42.
HamannAGarcia-PuigJPaulGDonaldsonJStewartM. Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with type 2 diabetes inadequately controlled on metformin alone. Exp Clin Endocrinol Diabetes.2008;116 (1): 6–13.
43.
HanleyAJZinmanBSheridanPYusufSGersteinHC; Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication (DREAM) Investigators. Effect of rosiglitazone and ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: The DREAM Trial. Diabetes Care.2010;33 (3): 608–13.
44.
DaviesMJMetcalfeJDayJLGrenfellAHalesCNGrayIP. Improved beta cell function, with reduction in secretion of intact and 32/33 split proinsulin, after dietary intervention in subjects with type 2 diabetes mellitus. Diabet Med.1994;11 (1): 71–8.
45.
BybergLZetheliusBMcKeiguePMLithellHO. Changes in physical activity are associated with changes in metabolic cardiovascular risk factors. Diabetologia.2001;44 (12): 2134–9.
46.
NagiDKAliVMYudkinJS. Effect of metformin on intact proinsulin and des 31, 32 proinsulin concentrations in subjects with non-insulin-dependent (type 2) diabetes mellitus. Diabet Med.1996;13 (8): 753–7.
47.
HermannLSRanstamJVaalerSMelanderA. Effects of antihyperglycaemic therapies on proinsulin and relation between proinsulin and cardiovascular risk factors in type 2 diabetes. Diabetes Obes Metab.1999;1 (4): 227–32.
48.
DaviesMJMetcalfeJDayJLGrenfellAHalesCNGrayIP. Effect of sulphonylurea therapy on plasma insulin, intact and 32/33 split proinsulin in subjects with type 2 diabetes mellitus. Diabet Med.1994;11 (3): 293–8.
49.
DworackaMAbramczykMWiniarskaHKuczynskiSBorowskaMSzczawinskaK. Disproportionately elevated proinsulin levels in type 2 diabetic patients treated with sulfonylurea. Int J Clin Pharmacol Ther.2006;44 (1): 14–21.
50.
PfütznerALorraBAbdollahniaMRKannPHMathieuDPehnertCOligschlegerCKaiserMForstT. The switch from sulfonylurea to preprandial short-acting insulin analog substitution has an immediate and comprehensive beta-cell protective effect in patients with type 2 diabetes mellitus. Diabetes Technol Ther.2006;8 (3): 375–84.
